2Moser HW,Loes D J,Melhem ER. X-linked adrenoleukodystrophy:overview and prognosis as a function of age and brain magnetic resonance imaging abnormality:A study involving 372 patients[J].Neuropediatrics,2000,(05):227.
3Tagawa Y, Laroy W, Nimfichter L et al. Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids. Neurochem Res,2002,27(7-8):847-855.
4Paintlia AS, Gilg AG, Khan M, et al. Correlation of very long chainfatty acids accumulation and inflammatory disease progression in childhood ALD: implications for potential therapies. Neurobiol Dis,2003,14(3) :425 -439.
5Mayatepek E, Baumann M, Meissner T, et al. Role of leukotfienes as indicators of the inflammatory demyelination reaction in X-linked cerebral adrenoleukodystrophy. J Neurol,2003, 250(10):1259-1260.
6Eichler FS, Itoh R, Barker PB, et al. Proton MR spectroscopic and diffusion tensor brain MR imaging in X -linked adrenoleukodystrophy: initial experience. Radiology,2002, 225(2):245-252.
7Geel BM, Assies J, Wanders R J, et al. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.J Neurol Neurosurg Psychiatry, 1997,63(1): 4-14.
4GREEN BN, JOHNSON CD. Writing patient case reports for peer-reviewed journals: secrets of the trade [J]. J Sports Chiropract Rehabil, 2000, 14 (3) :51 -59.
